These discoveries not merely determine NR4A1 to be a crucial modulator in cellular proliferation, thereby accelerating valvular calcification, but also present compelling evidence advocating for targeting NR4A1 may represent a potential therapeutic strategy for CAVD. Here, NR4A1 is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.